Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes

Trial Profile

Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 10 Nov 2017 According to a SymBio Pharmaceuticals media release, SymBio will promptly conduct an oral rigosertib/azacitidine combination trial in Japan after demonstrating the safety of high-dose oral rigosertib.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top